Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.

Source: Journal of Infection - February 29, 2024 Category: Infectious Diseases Authors: Gail Hayward, Ly-Mee Yu, Paul Little, Oghenekome Gbinigie, Milensu Shanyinde, Victoria Harris, Jienchi Dorward, Benjamin R Saville, Nicholas Berry, Philip H Evans, Nicholas PB Thomas, Mahendra G Patel, Duncan Richards, Oliver Van Hecke, Michelle A Detry, Source Type: research